Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALIGN Study of atrasentan in IgA nephropathy
2024-513227-16-00Phase 3Authorised
- Sponsor
- Novartis
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial of atrasentan in IgA nephropathy (IgAN) (4 arms), sponsored by Novartis. Planned start May 2021; status: authorised.
02
Drugs
atrasentan
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on 2024-513227-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513227-16-00.